Advantage Alpha Capital Partners’s Entrada Therapeutics TRDA Stock Holding History

Advantage Alpha Capital Partners’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-20	Closed	-$285	–	192
2024 Q2	$285	Sell	20 -91,096	-100%	-$1.29M	﹤0.01%	154
2024 Q1	$1.29M	Sell	91,116 -14,021	-13%	-$198K	0.24%	90
2023 Q4	$1.59M	Buy	+105,137	New	+$1.56M	0.3%	87

Other funds holding TRDA

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Advantage Alpha Capital Partners's TRDA Position: Q3 2024 in Review

Advantage Alpha Capital Partners sold out of Entrada Therapeutics (TRDA) in Q3 2024, closing a stake of 20 shares — an estimated $285 sold.

Advantage Alpha Capital Partners first reported a position in TRDA in Q4 2023 and held it in 3 quarters. The position peaked at $1.59M in Q4 2023. 97 funds tracked by Wall St. Rank hold TRDA as of Q3 2024.

Advantage Alpha Capital Partners reported no remaining Entrada Therapeutics position as of Q3 2024 after selling out during the quarter.
Advantage Alpha Capital Partners sold 20 Entrada Therapeutics shares in Q3 2024, an estimated $285.
Advantage Alpha Capital Partners first reported a position in Entrada Therapeutics in Q4 2023 and held it in 3 quarters.
Advantage Alpha Capital Partners's Entrada Therapeutics position peaked at $1.59M in Q4 2023.
97 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2024.

Based on Advantage Alpha Capital Partners's 13F filing for Q3 2024, filed 13 Nov 2024.